# Ulrike von Arnim

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ulrike-von-arnim/

## Facts

| Field | Value |
| --- | --- |
| Citations | 4,586 |
| Field | Eosinophilic Esophagitis |
| h-index | 27 |
| i10-index | 45 |
| OpenAlex ID | https://openalex.org/A5022980599 |
| ORCID iD | 0000-0003-3214-0166 |
| Works | 202 |

## Researcher papers

- [Guidelines on eosinophilic esophagitis: evidence‐based statements and recommendations for diagnosis and management in children and adults](https://scholariq.org/papers/guidelines-on-eosinophilic-esophagitis-evidence-based-statements-and/)
- [Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial](https://scholariq.org/papers/efficacy-of-budesonide-orodispersible-tablets-as-induction-therapy-for/)
- [A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis](https://scholariq.org/papers/a-randomised-double-blind-trial-comparing-budesonide-formulations-and-dosages/)
- [Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis](https://scholariq.org/papers/budesonide-orodispersible-tablets-maintain-remission-in-a-randomized-placebo/)
- [STW 5, a Phytopharmacon for Patients With Functional Dyspepsia: Results of a Multicenter, Placebo-Controlled Double-Blind Study](https://scholariq.org/papers/stw-5-a-phytopharmacon-for-patients-with-functional-dyspepsia-results-of-a/)
- [International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature](https://scholariq.org/papers/international-consensus-recommendations-for-eosinophilic-gastrointestinal/)
- [Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study](https://scholariq.org/papers/vedolizumab-provides-clinical-benefit-over-1-year-in-patients-with-active/)
- [Circulating and Fecal microRNAs as Biomarkers for Inflammatory Bowel Diseases](https://scholariq.org/papers/circulating-and-fecal-micrornas-as-biomarkers-for-inflammatory-bowel-diseases/)
- [A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B](https://scholariq.org/papers/a-multicenter-randomized-controlled-trial-of-nucleos-t-ide-analogue-cessation-in/)
- [Validity of A Modified 13C-Urea Breath Test for Pre- and Posttreatment Diagnosis of Helicobacter Pylori Infection in The Routine Clinical Setting](https://scholariq.org/papers/validity-of-a-modified-13c-urea-breath-test-for-pre-and-posttreatment-diagnosis/)
- [Long-Term Sequelae of SARS-CoV-2 Infection in Patients with Inflammatory Bowel Diseases Compared to Relatives with SARS-CoV-2 Infection without Inflammatory Bowel Disease and Inflammatory Bowel Disease Patients without SARS-CoV-2: Results of a Retrospective Case-Control Study](https://scholariq.org/papers/long-term-sequelae-of-sars-cov-2-infection-in-patients-with-inflammatory-bowel/)

## Researcher topics

- [Eosinophilic Esophagitis](https://scholariq.org/topics/eosinophilic-esophagitis/)
- [Eosinophilic Disorders and Syndromes](https://scholariq.org/topics/eosinophilic-disorders-and-syndromes/)
- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Microscopic Colitis](https://scholariq.org/topics/microscopic-colitis/)
- [Gastroesophageal reflux and treatments](https://scholariq.org/topics/gastroesophageal-reflux-and-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.